Impact of selection bias on the association of kidney function polygenic scores with CKD progression in populations with CKD
Open Access
- 5 October 2026
- journal article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Abstract
Background and hypothesis: The associations of polygenic scores (PGSs) for eGFR with clinical outcomes in prevalent CKD populations have not been well evaluated. Collider bias may distort associations of exposures (including PGS) with outcomes in populations with prevalent disease. Methods: Analyses included European ancestry participants from UK Biobank and three CKD cohorts (SHARP, CRIC, and EMPA-KIDNEY) without ESKD at baseline. The exposure was a PGS for low eGFR derived from a genome-wide association study (GWAS) of eGFR in the FinnGen cohort. The primary outcomes were eGFR slope (ml/min/1.73m2/year) and kidney disease progression (KDP; defined as first occurrence of incident dialysis, transplantation, sustained eGFR decline by ≥40%, or sustained eGFR <10 ml/min/1.73 m2). Associations between the PGS and eGFR slope were assessed by linear regression and meta-analysed across studies. Associations with KDP were assessed using Cox proportional hazards models. Results: A total of 107 536 participants in UKB and 6846 participants from CKD cohorts were included in analyses. In UKB, higher PGS was associated with lower baseline eGFR (−5.09 [−5.31; −4.86] ml/min/1.73 m2 for those in the top 10% of the PGS vs. the rest), with greater risk of KDP (HR 1.36 [1.20–1.55]) and faster eGFR decline (−0.12 [−0.14; −0.09] ml/min/1.73m2/year). However, in CKD cohorts, higher PGS was not associated with baseline eGFR (0.15 [−0.73; 1.03] ml/min/1.73 m2) but was associated with lower risk of KDP (HR 0.76 [0.66–0.89]), with a directionally consistent (though non-significant) effect on eGFR decline (+0.19 [−0.01; 0.39] ml/min/1.73m2/year). Conclusions: A PGS for low eGFR is associated with faster eGFR decline and higher risk of KDP in a population unselected for CKD, but when applied in populations with CKD, non-causal associations are introduced which artificially reverse the associations seen. Applying PGS in populations selected for prevalent disease may lead to qualitatively misleading conclusions on the direction of associations with clinical outcomes.Keywords
Funding Information
- Niilo Helanderin Säätiö
- National Institute on Handicapped Research
This publication has 28 references indexed in Scilit:
- Polygenic scores and their applications in kidney diseaseNature Reviews Nephrology, 2024
- Polygenic risk alters the penetrance of monogenic kidney diseaseNature Communications, 2023
- A polygenic score for reduced kidney function and adverse outcomes in a cohort with chronic kidney diseaseKidney International, 2022
- Kidney disease progression and collider bias in GWASKidney International, 2022
- Association of Albuminuria and Regression of Chronic Kidney Disease in Adults With Newly Diagnosed Moderate to Severe Chronic Kidney DiseaseJAMA Network Open, 2022
- Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studiesKidney International, 2022
- Genome-wide association meta-analyses and fine-mapping elucidate pathways influencing albuminuriaNature Communications, 2019
- A global reference for human genetic variationNature, 2015
- Haplotype Estimation Using Sequencing ReadsThe American Journal of Human Genetics, 2013
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011